Portal de Periódicos da CAPES

Effects of the onabotulinumtoxinA follow-up delay in migraine course during the COVID-19 lockdown

2021; Springer Science+Business Media; Volume: 42; Issue: 12 Linguagem: Inglês

10.1007/s10072-021-05180-8

1590-3478

Alicia González‐Martínez, Álvaro Planchuelo‐Gómez, Ángel Luis Guerrero Peral, David García‐Azorín, Sonia Santos‐Lasaosa, María Pilar Navarro‐Pérez, Paula Odriozola-González, María Jesús Irurtia Muñiz, Sonia Quintas, Rodrigo de Luis-Garcı́a, Ana Beatriz Gago‐Veiga,

Psychosomatic Disorders and Their Treatments

Face-to-face procedures have been postponed during COVID-19 pandemic. We aim to evaluate the impact of onabotulinumtoxinA follow-up delay in migraine during COVID-19 pandemic. Subjective worsening, intensity of migraine attacks, and frequency of headache and migraine were retrospectively compared between patients with unmodified and interrupted onabotulinumtoxinA follow-up in Headache Units. We included 67 patients with chronic migraine or high-frequency episodic migraine under onabotulinumtoxinA treatment, 65 (97.0%) female, 44.5 ± 12.1 years old. Treatment administration was voluntarily delayed in 14 (20.9%) patients and nine (13.4%) were unable to continue follow-up. Patients with uninterrupted follow-up during lockdown presented 7.6 and 8.1 less monthly days with headache (adjusted p = 0.017) and migraine attacks (adjusted p = 0.009) compared to patients whose follow-up was interrupted, respectively. Involuntary delay of onabotulinumtoxinA follow-up in patients with migraine due to COVID-19 pandemic was associated with a higher frequency of headache and migraine attacks. Safe administration of onabotulinumtoxinA during lockdown should be promoted.